Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
Rhea-AI Summary
Crinetics Pharmaceuticals (Nasdaq: CRNX) will report Q1 2026 financial results on Thursday, May 7, 2026 after market close and host a conference call at 4:30 p.m. ET.
Dial-in numbers and Meeting ID are provided for domestic and international participants, and a live webcast will be available and archived on the company Investor Relations website.
Positive
- None.
Negative
- None.
News Market Reaction – CRNX
In the Apr 9 session, CRNX declined 0.83%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 26 | Earnings date announcement | Neutral | +0.8% | Set date and time for Q4 and full-year 2025 earnings call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings-date scheduling news saw a modest positive price reaction of 0.85% the next day.
Recent news flow for Crinetics includes regulatory and commercial milestones alongside capital markets activity. In January 2026, the company scheduled its Q4 and full-year 2025 results call, which was followed by a 0.85% gain over 24 hours. Subsequent updates covered a Phase 2/3 pediatric trial initiation, Q4 and full-year 2025 financials with a business update, and a Brazil Marketing Authorization Application for PALSONIFY. Today’s announcement similarly sets the timing and logistics for the upcoming Q1 2026 earnings release and conference call.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
Conference Call & Webcast
Thursday, May 7 at 4:30 p.m. ET
| Domestic: | 1 833-461-5787 |
| International: | 1 585-542-9983 |
| Meeting ID: | 173777518 |
Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call.
The webcast will be archived on the Investor Relations section of www.crinetics.com.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.
Crinetics’ lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and CRN09682, a nonpeptide drug conjugate candidate that is being developed to treat SST2 expressing neuroendocrine tumors and other SST2 expressing solid tumors. Additional discovery programs address a variety of endocrine conditions such as neuroendocrine tumors, Graves’ disease (including Graves’ hyperthyroidism and Graves’ orbitopathy, or thyroid eye disease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075
